Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

Sanjiv S. Agarwala, MD
Published: Tuesday, Sep 04, 2018



Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Pembrolizumab (Keytruda) is a PD-1 inhibitor that has shown efficacy in melanoma, Agarwala says. Unfortunately, there are a number of patients who either don’t respond to immunotherapy or become refractory to treatment over time. One of the most common ongoing questions in oncology is to figure out how to make immunotherapy-refractory patients respond to this type of treatment again. There have been many combinations designed to do just that, with one of them including HDAC inhibitors like entinostat, which affect the tumor microenvironment.

The design of the study Agarwala presented at the 2018 ASCO Annual Meeting took patients with melanoma who became refractory to anti–PD-1/PD-L1 treatment and determine whether they would respond to pembrolizumab with the addition of entinostat.


Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Pembrolizumab (Keytruda) is a PD-1 inhibitor that has shown efficacy in melanoma, Agarwala says. Unfortunately, there are a number of patients who either don’t respond to immunotherapy or become refractory to treatment over time. One of the most common ongoing questions in oncology is to figure out how to make immunotherapy-refractory patients respond to this type of treatment again. There have been many combinations designed to do just that, with one of them including HDAC inhibitors like entinostat, which affect the tumor microenvironment.

The design of the study Agarwala presented at the 2018 ASCO Annual Meeting took patients with melanoma who became refractory to anti–PD-1/PD-L1 treatment and determine whether they would respond to pembrolizumab with the addition of entinostat.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x